231 related articles for article (PubMed ID: 30545834)
21. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
22. Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation.
El-Bietar J; Warren M; Dandoy C; Myers KC; Lane A; Wallace G; Davies SM; Jodele S
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1994-2001. PubMed ID: 26150023
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
[TBL] [Abstract][Full Text] [Related]
24. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research.
Buchbinder D; Nugent DJ; Brazauskas R; Wang Z; Aljurf MD; Cairo MS; Chow R; Duncan C; Eldjerou LK; Gupta V; Hale GA; Halter J; Hayes-Lattin BM; Hsu JW; Jacobsohn DA; Kamble RT; Kasow KA; Lazarus HM; Mehta P; Myers KC; Parsons SK; Passweg JR; Pidala J; Reddy V; Sales-Bonfim CM; Savani BN; Seber A; Sorror ML; Steinberg A; Wood WA; Wall DA; Winiarski JH; Yu LC; Majhail NS
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1776-84. PubMed ID: 22863842
[TBL] [Abstract][Full Text] [Related]
25. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.
Veeraputhiran M; Yang L; Sundaram V; Arai S; Lowsky R; Miklos D; Meyer E; Muffly L; Negrin R; Rezvani A; Shizuru J; Weng WK; Johnston L
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1744-1748. PubMed ID: 28668491
[TBL] [Abstract][Full Text] [Related]
26. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
Srinivasan R; Takahashi Y; McCoy JP; Espinoza-Delgado I; Dorrance C; Igarashi T; Lundqvist A; Barrett AJ; Young NS; Geller N; Childs RW
Br J Haematol; 2006 May; 133(3):305-14. PubMed ID: 16643433
[TBL] [Abstract][Full Text] [Related]
27. Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.
Vaughn JE; Gooley T; Maziarz RT; Pulsipher MA; Bhatia S; Maloney DG; Sandmaier BM; Flowers ME; Storb R; Sorror ML
Br J Haematol; 2015 Nov; 171(3):411-6. PubMed ID: 26194447
[TBL] [Abstract][Full Text] [Related]
28. Guest Editorial: Inherited bone marrow failure and myelodysplasia in children: how much do we know about pediatric diseases?
Manabe A
Int J Hematol; 2016 Apr; 103(4):359. PubMed ID: 26899856
[No Abstract] [Full Text] [Related]
29. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
30. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up.
Alter BP; Giri N; Savage SA; Rosenberg PS
Haematologica; 2018 Jan; 103(1):30-39. PubMed ID: 29051281
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
32. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia.
Ngwube A; Hayashi RJ; Murray L; Loechelt B; Dalal J; Jaroscak J; Shenoy S
Pediatr Blood Cancer; 2015 Jul; 62(7):1270-6. PubMed ID: 25755151
[TBL] [Abstract][Full Text] [Related]
33. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
[TBL] [Abstract][Full Text] [Related]
34. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.
Maury S; Balère-Appert ML; Chir Z; Boiron JM; Galambrun C; Yakouben K; Bordigoni P; Marie-Cardine A; Milpied N; Kanold J; Maillard N; Socié G;
Haematologica; 2007 May; 92(5):589-96. PubMed ID: 17488681
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children.
Forlanini F; Zinter MS; Dvorak CC; Bailey-Olson M; Winestone LE; Shimano KA; Higham CS; Melton A; Chu J; Kharbanda S
Transplant Cell Ther; 2022 Mar; 28(3):155.e1-155.e8. PubMed ID: 34848362
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.
Burroughs LM; Shimamura A; Talano JA; Domm JA; Baker KK; Delaney C; Frangoul H; Margolis DA; Baker KS; Nemecek ER; Geddis AE; Sandmaier BM; Deeg HJ; Storb R; Woolfrey AE
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1669-1677. PubMed ID: 28602958
[TBL] [Abstract][Full Text] [Related]
37. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan.
Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Ghafoor T; Shamshad GU; Farhan M; Shahbaz N; Khan MA; Khattak TA; Rehman J; Humayun S; Satti HS; Anwer F; Ahmed P
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2375-2382. PubMed ID: 31394274
[TBL] [Abstract][Full Text] [Related]
38. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.
Wang Y; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Lee SJ; Savage SA; Gadalla SM
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1054-1058. PubMed ID: 28389255
[TBL] [Abstract][Full Text] [Related]
39. Late Mortality after Allogeneic Bone Marrow Transplantation in Childhood for Bone Marrow Failure Syndromes and Severe Aplastic Anemia.
Holmqvist AS; Chen Y; Wu J; Battles K; Francisco L; Hageman L; Kung M; Ness E; Parman M; Winther JF; Rosenthal J; Arora M; Armenian SH; Bhatia S
Biol Blood Marrow Transplant; 2019 Apr; 25(4):749-755. PubMed ID: 30578940
[TBL] [Abstract][Full Text] [Related]
40. Reduced-intensity conditioning (RIC) in children with nonmalignant disorders (NMD) undergoing unrelated donor umbilical cord blood transplantation (UCBT).
Parikh S; Szabolcs P
Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S53-5. PubMed ID: 22226113
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
